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Nucleotide excision repair is a highly versatile DNA
repair system responsible for elimination of a wide va-
riety of lesions from the genome. It is comprised of two
subpathways: transcription-coupled repair that accom-
plishes efficient removal of damage blocking transcrip-
tion and global genome repair. Recently, the basic mech-
anism of global genome repair has emerged from
biochemical studies. However, little is known about
transcription-coupled repair in eukaryotes. Here we re-
port the identification of a novel protein designated
XAB2 (XPA-binding protein 2) that was identified by
virtue of its ability to interact with XPA, a factor central
to both nucleotide excision repair subpathways. The
XAB2 protein of 855 amino acids consists mainly of 15
tetratricopeptide repeats. In addition to interacting
with XPA, immunoprecipitation experiments demon-
strated that a fraction of XAB2 is able to interact with
the transcription-coupled repair-specific proteins CSA
and CSB as well as RNA polymerase II. Furthermore,
antibodies against XAB2 inhibited both transcription-
coupled repair and transcription in vivo but not global
genome repair when microinjected into living fibro-
blasts. These results indicate that XAB2 is a novel com-
ponent involved in transcription-coupled repair and
transcription.
NER1 is a highly versatile and strongly conserved DNA
damage repair pathway. It maintains the genetic information
by removing a wide variety of lesions from DNA including
UV-induced cyclobutane pyrimidine dimers and 6/4 photoprod-
ucts as well as numerous chemical adducts (1). Two subpath-
ways can be discerned in NER: global genome repair (GGR) and
transcription-coupled repair (TCR) (2). Lesions that actually
block transcription, such as cyclobutane pyrimidine dimers
(which are inefficiently removed by GGR), are preferentially
removed from the transcribed strand of active genes by TCR to
allow rapid recovery of RNA synthesis (3, 4).
The importance of NER is highlighted by the clinical features
of rare human hereditary conditions caused by a deficiency in
NER, such as xeroderma pigmentosum (XP) and Cockayne
syndrome (CS). XP patients show striking hypersensitivity to
sunlight and an extremely high incidence of skin cancer in
sun-exposed areas and frequently progressive neurological de-
generation. Seven genetic complementation groups of XP are
known, XP-A through XP-G. In addition, an XP variant group
(XP-V) is defective in postreplication repair (5). Cells from
XP-C patients are deficient only in GGR but not in TCR (6, 7).
CS patients show photohypersensitivity, cachectic dwarfism,
and severe mental retardation but, unlike XP patients, no
predisposition to skin cancer (8). Two genetic complementation
groups exist: CS-A and CS-B. In contrast to XP-C, the defect
within CS is restricted to TCR (9, 10). To date, all of the known
genes responsible for XP and CS (the XPA-XPG, XPV, CSA, and
CSB genes) have been cloned (5).
Recently, the core reaction of NER in humans has been
reconstituted in vitro with purified proteins (11–13), and the
outlines of the mechanism of GGR have been elucidated (re-
viewed in Ref. 14). The XPC-HR23B complex is the main factor
to initiate global genome repair by sensing and binding to
various types of lesion (15). The UV-DDB protein complex that
is affected in XP-E patients is required for recognition of a
specific subset of damage, such as cyclobutane pyrimidine
dimers (16). The binding of XPC-HR23B complex to a lesion
presumably induces a conformational change in the DNA
around the injury. TFIIH, a general transcription initiation
factor containing the XPB and XPD DNA helicases, is recruited
to the recognized injury and locally unwinds the DNA duplex
by its bidirectional DNA helicase activities to form an open
reaction intermediate. XPA in a complex with replication pro-
tein A is likely to be involved in verification of the damage,
proper orientation of the NER machinery around the injury,
and stabilization of the opened intermediate. At the same time,
replication protein A positions the structure-specific endo-
nucleases at the appropriate sites for dual incision: XPG 2–8
bases at the 39 side and the ERCC1-XPF complex 15–24 nucle-
otides 59 of the lesion. After removal of the damage-containing
24–32-mer oligonucleotide, the resulting gap in the DNA is
filled by general replication factors, and the final nick is sealed
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by DNA ligase (see Refs. 14 and 17 for recent reviews and
specific references therein).
The molecular mechanism of TCR is only resolved for Esch-
erichia coli (18). The Mfd gene product (containing helicase
motifs but without helicase activity) has been identified as a
transcription-repair coupling factor that displaces an elongat-
ing RNA polymerase blocked in front of a lesion and then
recruits the UvrABC E. coli excinuclease, which accomplishes
removal of the lesion. In humans, genetic and cell biological
evidence indicates that CSA and CSB play a key role in TCR (9,
10), but their functions remain to be elucidated. CSA is a
44-kDa protein with WD-40 repeats, which appears to have a
potential for interaction with other proteins. It has been re-
ported that CSA interacts with CSB and the p44 subunit of
TFIIH in vitro (19). CSB is a 168-kDa protein with helicase
motifs that belongs to the SWI/SNF family (20). We have pre-
viously shown that CSB is associated with RNA polymerase II
in vivo (21), and we and others have shown that CSB has a
DNA-dependent ATPase activity but no detectable classical
helicase activity (22, 23). Since both CSB and Mfd contain
helicase motifs, CSB may play a role equivalent to Mfd in
mammalian cells. However, unlike Mfd, CSB has no detectable
activity to dissociate RNA polymerase II stalled at a lesion from
the DNA (24). It has been shown that CSB interacts with RNA
polymerase II in a complex containing DNA and nascent RNA
in vitro (25). The resulting quaternary complex has been shown
to have an ability to recruit TFIIH, suggesting that CSB would
recruit the NER proteins in vivo when RNA polymerase II
encounters the lesion on the transcribed strand (26).
In the present study, we isolated a cDNA encoding a novel
tetratricopeptide repeat (TPR) protein, designated XAB2 (XPA-
binding protein 2). We found that XAB2 associates with both
TCR-specific factors CSA and CSB and with RNA polymerase
II. Furthermore, microinjection of anti-XAB2 antibodies specif-
ically inhibited transcription as well as TCR but not GGR,
suggesting that XAB2 is a novel factor participating in TCR
and transcription itself.
EXPERIMENTAL PROCEDURES
Yeast Two-hybrid System—Screening of a HeLa cDNA library for
isolating cDNAs encoding XPA binding proteins was performed using
the yeast two-hybrid system as described (27). Positive transformants
were classified into several groups based on cross-hybridization. Out of
281 positive clones, 54 belonged to the group of XAB2. To obtain full-
length cDNA of XAB2, we screened a HeLa cDNA library in l ZAP II
(provided by Dr. H. Nojima, Osaka University) using the 939-base pair
SmaI fragment of XAB2 cDNA as a probe. In addition, 59-rapid ampli-
fication of cDNA ends was performed with 59-AmpliFINDER RACE KIT
(CLONTECH) using the P1 primer (59-TTCATAGGCAGGGTCGGTCA-
CACAG-39) and P2 primer (59-TGTGCCCGACGCGCCTTCAGGTATC-
39) according to the protocol supplied by the manufacturer. The full-
length cDNA of XAB2 was reconstructed in pBluescript SK(2) by
insertion of the EcoRI–KpnI fragment from the rapid amplification of
cDNA ends product into the EcoRI and KpnI sites of the cDNA from the
HeLa l Zap library screenings.
In Vitro Pull-down Assay—Glutathione S-transferase (GST)-XPA
fusion protein was prepared as described previously (27). GST-XAB2
fusion protein was obtained by in-frame cloning the full-length XAB2
cDNA into pGEX-5X-2 (Amersham Pharmacia Biotech). Referring to
the published data (19), the CSA cDNA was isolated from WI38 VA13
cells with RT-PCR using an upper primer (59-CGAATTCTCGAG-
GATATGCTGGGGTTTTTGTC-39) with an EcoRI site and a lower
primer (59-TTGGTCGACTCTGTTTTAGGATTTTATGCAAA-39) with a
SalI site. The amplified product was digested with EcoRI and SalI and
inserted into pBluescript SK(2) and pGEX-5X-2 for in vitro translation
and GST fusion protein, respectively. In vitro translation of proteins
and pull-down assays using GST, GST-XAB2, or GST-CSA fusion pro-
tein were performed as described (27).
Anti-XAB2 Antisera—Two antisera were prepared. Anti-XAB2FL
was raised against the full-length recombinant XAB2, obtained using
BAC-to-BAC Baculovirus Expression System (Life Technologies, Inc.).
The EcoRI–XhoI fragment containing the full-length cDNA of XAB2
was inserted into pFASTBAC1 (Life Technologies, Inc.) plasmid, and
then the recombinant baculoviruses were obtained by following the
instruction manual. Sf9 cells (1 3 108 cells) were infected with the
recombinant baculoviruses at 27 °C at a multiplicity of infection of 0.5.
After 3 days of incubation, cells were harvested and washed twice with
ice-cold PBS. The cell pellet was resuspended in NETN buffer (150 mM
NaCl, 1 mM EDTA, 50 mM Tris-HCl (pH 7.8), 1% Nonidet P-40, 1 mM
phenylmethylsulfonyl fluoride, 0.5 mg/ml leupeptin, and 0.5 mg/ml pep-
statin), and the suspension was centrifuged at 12,000 3 g for 20 min.
Almost all of the recombinant XAB2 were recovered in the pellet. After
washed with NETN buffer, the pellet was dissolved in SDS sample
buffer and then applied to SDS-polyacrylamide gel electrophoresis on
7% polyacrylamide gel. To visualize the recombinant XAB2, the gel was
stained with CBB-R250 and destained in water. The gel stripe contain-
ing the recombinant XAB2 was cut out and used for immunization.
Anti-XAB2C was raised against the C-terminal part (amino acid resi-
dues 694–855) of XAB2, overproduced as a GST fusion product in E.
coli. The BglII–XhoI fragment of XAB2 cDNA was inserted into BamHI
and XhoI sites of pGEX-5X-2. The GST fusion C-terminal 162 amino
acids of XAB2 were purified with glutathione-Sepharose beads (Amer-
sham Pharmacia Biotech) in NETN buffer.
Immunoprecipitation—To examine the interactions of XAB2 with
CSA, we used the SV40-transformed CS-A fibroblast line CS3BE-SV
and CS3BE-SV(dtCSA) cells. CS3BE-SV expressed no endogenous CSA,
while CS3BE-SV(dtCSA) stably expressing hemagglutinin (HA)-/His6-
double-tagged CSA at physiological levels showed a normal UV sensi-
tivity.2 Whole cell extracts (WCE) of these cells were prepared with
NETN buffer as described previously (27). The WCE (4 mg) was incu-
bated with 5 mg of anti-HA mouse monoclonal antibody (12CA5) at 4 °C
for 12 h. The immunocomplexes were subsequently precipitated with 40
ml (bed volume) of Protein G-Sepharose beads (Amersham Pharmacia
Biotech). After extensive washing with NETN buffer, bound proteins
were eluted by boiling in SDS sample buffer. To examine the interac-
tions of XAB2 with CSB, the SV40-transformed CS1AN-SV (2tCSB) cell
line (stably expressing functional and physiological levels of HA-/His6-
double-tagged CSB) and HeLa cells were used for preparing Manley’s
WCE as described previously (21). The WCE (4 mg) was incubated with
5 mg of anti-HA mouse monoclonal antibody (12CA5) at 4 °C for 6 h. The
protein-antibody complexes were subsequently bound to Protein G-
Sepharose beads (Amersham Pharmacia Biotech). After extensive
washing with buffer A (25 mM HEPES-KOH (pH 7.9), 100 mM KCl, 10%
glycerol, 0.1% Nonidet P-40, 1 mM 2-mercaptoethanol, 0.1 mM phenyl-
methylsulfonyl fluoride), bound proteins were eluted by incubation with
a synthetic HA-peptide (YPYDVPDYA) at 1 mg/ml in buffer A. For
co-immunoprecipitation of XAB2 with RNA polymerase II, HeLa WCE
(4 mg), prepared with NETN, was incubated with anti-RNA polymerase
II mouse monoclonal antibody (8WG16; a kind gift from Dr. J-M. Egly,
CNRS/INSERM/Universite´ Louis Pasteur) or anti-XAB2FL at 4 °C for
12 h. The immunocomplexes were purified in NETN buffer as described
above, and bound proteins were eluted by boiling in SDS sample buffer.
The proteins in the eluates (immunoprecipitated fractions) were sepa-
rated on SDS-polyacrylamide gel electrophoresis and subjected to im-
munoblot analyses. The WCEs (20 mg) were also subjected to immuno-
blot analyses with the immunoprecipitated fractions. Anti-HA rat
monoclonal antibody (3F10) was used to detect HA-tagged CSA and
CSB.
Microinjection—Microinjections were performed into homopolykary-
ons of DNA repair-proficient control primary fibroblasts (C5RO) and
XP21RO (XP-C) cells obtained after cell fusion as described (21). NER
activity (unscheduled DNA synthesis (UDS)) was measured 24 h after
injection. After microinjection, cells were UV-irradiated at 15 J/m2 and
then subjected to a 2-h incubation in culture medium containing
[3H]thymidine (20 mCi/ml; specific activity, 120 Ci/mmol) washed with
PBS, fixed, and processed for autoradiography. Recovery of RNA syn-
thesis (RRS) after UV irradiation was determined as follows. 24 h after
injection, cells were exposed to 15 J/m2 of UV light, incubated for an
additional 24 h in normal culture medium, washed with PBS, and
subsequently incubated for another 1 h in culture medium containing
[3H]uridine (10 mCi/ml; specific activity, 50 Ci/mmol), fixed, and pro-
cessed for autoradiography. Overall normal RNA synthesis (transcrip-
tion) was determined, 48 h after injection as described above for RRS
but without prior UV irradiation. UDS, RRS, and transcription levels
were quantified by counting the autoradiographically induced silver
grains above the nuclei (at least 100 nuclei). The relative levels of repair
and transcription in the injected cells were obtained by dividing the
2 E. Citterio, unpublished results.
A Novel TPR Protein in DNA Repair and Transcription34932
mean grain count number by the number of grains above the nuclei of
surrounding noninjected cells.
RESULTS
XAB2 Is an XPA-interacting Protein—To identify protein
interactions within NER and/or with other nuclear constitu-
ents, we performed a yeast two-hybrid screen with XPA as a
bait (27) (see “Experimental Procedures”). In addition to pre-
viously identified XPA-interacting NER proteins (such as
ERCC1 (28, 29) and the p34 subunit of replication protein A
(27, 30)), we isolated a cDNA encoding a novel protein, desig-
nated XAB2 (XPA-binding protein 2). The specific interaction of
XPA and XAB2 in yeast (Fig. 1A) was confirmed by in vitro
pull-down assays using GST-XPA fusion protein and in vitro
translated XAB2 (Fig. 1B).
XAB2 Is a Novel Tetratricopeptide Protein—Sequencing of
the complete cDNA (reconstructed after 59-rapid amplification
of cDNA ends; see “Experimental Procedures”) revealed a pre-
dicted acidic protein (pI 5.8) of 855 amino acids containing
three stretches of acidic residues (Figs. 2 and 3A). Sequence
homology searches using NCBI PSI-BLAST to match the XAB2
sequence against sequences in nonredundant protein data
bases revealed three apparent homologs of Drosophila melano-
gaster (ORF of CG6197, accession number AAF58348; 60.6%
identical), Caenorhabditis elegans (ORF of C50F2.3, accession
number AAB37794; 47.5% identical), and Schizosaccharomyces
pombe (ORF of SPBC211.02c, accession number CAB75410;
40.5% identical) (31). The searches also revealed that SYF1 is
a most homologous protein in Saccharomyces cerevisiae, al-
though the overall homology is not as high as in the other
species (23.8% identical). The alignment of these proteins with
XAB2 is shown in Fig. 2. The function of these proteins has not
been identified. However, the strong conservation of XAB2
observed between lower and higher eukaryotes suggests the
importance of this protein. The SYF1 gene had been identified
as a synthetic lethal mutant with the CDC40/PRP17 gene,
which is involved in S phase progression of the cell cycle and
pre-mRNA splicing in S. cerevisiae (47). The homology observed
between XAB2 and SYF1 gives rise to a possibility that in
addition to NER, XAB2 may be involved in cell cycle control
and pre-mRNA splicing (see “Discussion”). The alignment of
these proteins also revealed that the carboxyl-terminal portion
(29 amino acid residues at positions 825–853) of XAB2 is con-
served in the D. melanogaster and C. elegans proteins, but
absent in the S. pombe and S. cerevisiae proteins (Fig. 2). This
region may have a specific role only in multicellular organisms.
The apparent homologs of XAB2 listed above contain TPRs
that are degenerate repeats composed of 34-amino acid motifs
(33). Three classes of TPR (classes I–III) are categorized based
on the conserved sequences (34). TPRs are found in proteins of
different organisms ranging from bacteria to humans impli-
cated in protein complexes with diverged functions such as cell
cycle control, transcriptional regulation, RNA processing, and
mitochondrial and peroxisomal protein transport (35, 36). Mu-
tational and structural analyses suggest that TPR domains
play a role in intra- and intermolecular protein interactions
(37–39). Sequence analysis revealed that XAB2 has 15 motifs of
the class I TPR covering most of the protein (Figs. 2 and 3),
suggesting that XAB2 may function as an important factor for
protein-complex formations in NER.
XAB2 Interacts with CSA, CSB, and RNA Polymerase II—
Since TPR proteins have been frequently found in complexes
with WD-40 repeat-containing polypeptides (40, 41), we fo-
cused on the CSA protein, the known NER factor containing
WD-40 repeats (19). As shown in Fig. 4A, in vitro translated
XAB2 was indeed able to bind to GST-CSA fusion protein, and
inversely in vitro translated CSA interacted with GST-XAB2
fusion protein. To verify the interaction in vivo, immunopre-
cipitations were performed using WCE of CS-A cells stably
expressing functional HA-tagged CSA (see “Experimental Pro-
cedures”). Anti-HA monoclonal antibodies co-immunoprecipi-
tated a small but significant fraction of XAB2 together with
HA-tagged CSA (Fig. 4B), suggesting that at least part of XAB2
is associated with CSA in vivo.
The interaction with CSA prompted us to examine whether
XAB2 interacts with CSB as well, since both CS proteins are
specifically involved in the TCR pathway. Using WCE of CS-B
cells stably expressing physiological levels of functional HA-/
His6-double-tagged CSB (2tCSB) (see Ref. 21 for documenta-
tion of these cells), immunoprecipitations with anti-HA mono-
clonal antibodies revealed an association of significant
quantities of XAB2 with CSB (Fig. 5A, upper part). This im-
munoprecipitated fraction also contained a significant propor-
tion of RNA polymerase II, as we have previously shown (21).
The XAB2-CSB interaction is specific, since neither endoge-
nous CSB nor XAB2 was precipitated with the anti-HA anti-
body when a WCE of HeLa without expression of 2tCSB was
used (Fig. 5A, lower part).
Previously, we have shown that CSB together with RNA
polymerase II is a part of a large protein complex (.700 kDa)
(21). Immunoblot analysis of HeLa WCE, fractionated under
physiological salt conditions by Superdex-200, revealed that
XAB2 is present in fractions with an estimated molecular mass
of .700 kDa (Fig. 5B), whereas a monomer of XAB2 is approx-
imately 100 kDa. The migration pattern of XAB2 largely coin-
cides with that of RNA polymerase II and CSB and differed
from other NER and transcription factors assayed in the same
fractions, such as ERCC1 (which forms a complex with XPF)
and the XPB subunit of TFIIH, both migrating with a lower
apparent molecular mass. The association of XAB2 with RNA
polymerase II is further supported by an identical co-migration
of the two proteins in the presence of 1 M KCl (Fig. 5B, lower
panel), suggesting that the interaction is highly salt-resistant.
In agreement with these observations, RNA polymerase II
large subunit and XAB2 co-immunoprecipitated from HeLa
WCE (Fig. 5C). RNA polymerase II large subunit was detected
in the immunoprecipitated fraction with anti-XAB2 antiserum
but absent in the fraction with control serum (Fig. 5C, a).
FIG. 1. A novel protein, XAB2, interacts with XPA. A, yeast
two-hybrid assay showing a specific interaction of XPA and XAB2. A
yeast strain expressing both XPA fused to the Gal4 DNA-binding do-
main and XAB2 fused to the Gal4 activation domain showed clear
b-galactosidase activity (numerous blue colonies apparent in 2). No
b-galactosidase activity was induced in yeast strains expressing XPA
fused to the Gal4 DNA-binding domain and the Gal4 activation domain
(without XAB2) (2) or the Gal4 DNA-binding domain (without XPA) and
XAB2 fused to the Gal4 activation domain (3). The enzyme activities
measured by a quantitative liquid assay are shown in the table on the
right. B, in vitro pull-down assays using in vitro translated, [35S]Met-
labeled XAB2 with GST or GST-XPA. 53 amounts of [35S]Met-labeled
XAB2 in the left lane (20% Input) were used for pull-down assays.
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Conversely, anti-RNA polymerase II (large subunit) antibodies
but not anti-HA control antibodies precipitated part of XAB2
from HeLa WCE (Fig. 5C, lower panel). These findings provide
evidence that XAB2 interacts with the CSB-RNA polymerase II
complex in vivo.
In Vivo Function of XAB2—The interactions of XAB2 with
XPA, CSA, and CSB-RNA polymerase II complex suggest a
possible role for XAB2 in the TCR subpathway of NER. To
further analyze the XAB2 function in living cells, we examined
the effect of microinjected anti-XAB2 antisera on various NER
parameters. Two antisera were used, one raised against the
full-length XAB2 and the other against the C-terminal part
(amino acid residues 694–855), designated anti-XAB2FL and
anti-XAB2C, respectively. Microinjection of both anti-XAB2FL
and anti-XAB2C did not significantly inhibit UV-induced UDS
of normal human fibroblasts, which is mainly derived from
FIG. 2. XAB2 amino acid sequence aligned with related proteins from four different species. The sequences are XAB2 (Homo sapiens),
ORF of CG6197 (D. melanogaster; AAF58348), ORF of C50F2.3 (C. elegans; AAB37794), ORF of SPBC211.02c (S. pombe; CAB75410), and SYF1
(S. cerevisiae; NP_010704). Identical amino acid residues are shown in darkly shaded boxes, and conservative substitutions are shown in lightly
shaded boxes. Underlines with Roman numerals indicate the regions of TPR motifs.
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GGR (42) (Fig. 6A and Table I). In contrast, injection of anti-
XAB2 antisera in fibroblasts of XP-C patients, carrying a spe-
cific defect in GGR, induced a significant reduction of the
residual UDS (Table I). Since UDS in XP-C cells is derived only
from TCR (6), these results suggest that anti-XAB2 antisera
directly interfere with the TCR rather than the GGR pathway.
The finding that both anti-XAB2 antisera also inhibited the
recovery of RNA synthesis after UV irradiation (RRS) in nor-
mal human cells (Fig. 6B and Table I) is consistent with the
above observations, since the failure of RRS is ascribed to the
defect of TCR (20, 43). Anti-CSB antiserum induced a similar
effect on the above NER parameters (Table I), whereas injected
anti-ERCC1 antiserum affected both subpathways of NER,
consistent with its essential function both in TCR and GGR.
Injection of preimmune serum (Table I) or a number of other
nonimmune sera and antibodies against various non-NER pro-
teins (data not shown) did not induce any effect on DNA repair
in normal human fibroblasts, indicating that the effect of XAB2
antisera is highly specific. The inhibitory effect of anti-XAB2
antisera on the process of TCR indicates that this protein plays
a role in the same pathway as the CS proteins. However, in
contrast to anti-CSB antiserum, anti-XAB2FL also induced a
significant inhibition of normal RNA synthesis (Fig. 6C and
Table I). This inhibitory effect was not observed using anti-
XAB2C (Table I), suggesting that the C-terminal region (amino
acid residues 694–855) of XAB2 may play an important role in
TCR but not in transcription itself.
As previously shown, injection of nonimmune sera as well as
antibodies against other factors only involved in NER failed to
exert inhibition of transcription, in contrast to antisera against
various proteins implicated in both NER and transcription
initiation (21, 44). In conclusion, the results of the antiserum
microinjection experiments suggest that XAB2 functions both
in TCR and in normal transcription but has no role in GGR.
DISCUSSION
We found a novel protein, XAB2, which interacts with TCR-
specific CSA, CSB proteins, and RNA polymerase II as well as
FIG. 3. XAB2 has 15 TPR motifs. A, schematic representation of the
XAB2 protein. Open boxes with numbers and hatched boxes indicate
TPR motifs and acidic regions, respectively. B, TPR sequence align-
ment. The 15 repeats in the predicted XAB2 protein were aligned. Dark
shading, amino acid residues found in more than eight out of the 15
repeats; light shading, conservative substitutions found in more than
seven of the 15 repeats. The substitutions were based on the following
groupings: Phe, Tyr, and Trp; Ser, Thr, Ala, Gly, and Pro; Ile, Leu, Val,
and Met; Asp, Glu, Asn, and Gln; and Arg, His, and Lys. Gaps in the
sequence alignments are indicated by dashes. Numbering to the right
corresponds to the amino acid positions of the TPRs in the XAB2 amino
acid sequence. Five amino acid residues (RCVTD; 85–89) were deleted
from TPR2 in the alignment. C, consensus sequence of TPRs in XAB2.
The XAB2 consensus sequence is aligned with the consensus of the
three classes of TPRs (34). The residues found most frequently at each
position in the TPRs of XAB2 were used in the XAB2 consensus se-
quence. More variable positions are represented by dots.
FIG. 4. Association of XAB2 with CSA. A, in vitro binding of XAB2
with CSA. In vitro pull-down assays were performed using in vitro
translated, [35S]Met-labeled XAB2 or [35S]Met-labeled CSA with GST,
GST-CSA, or GST-XAB2. B, co-immunoprecipitation of XAB2 with
CSA. WCEs and immunoprecipitated fractions of WCE from CS3BE-SV
cells with (1) or without (2) the expression of HA-CSA were analyzed
by immunoblotting using anti-XAB2FL antiserum (upper panels) or
anti-HA rat monoclonal antibody (3F10; lower panels; the lighter sig-
nals in both lanes are the heavy chain of mouse monoclonal antibody
12CA5 used for the immunoprecipitation).
FIG. 5. Interaction of XAB2 with CSB and RNA polymerase II.
A, co-immunoprecipitation of XAB2 with CSB. Immunoprecipitations
with anti-HA mouse monoclonal antibody 12CA5 were performed using
WCE of CS1AN-SV (2tCSB) cells (top) or HeLa cells (bottom). WCE
(lane 1), nonbound fraction (lane 2), and the fraction eluted with HA
peptide (lane 3) were analyzed with the indicated antibody. B, immu-
noblot analyses of size-fractionated WCE. HeLa WCE was separated on
a Superdex-200 column at 0.1 M KCl (top) or 1.0 M KCl (bottom).
Immunoblot analysis of the collected fractions was performed with the
indicated antisera. The sizes and positions of molecular weight markers
are shown at the top of the blots. C, co-immunoprecipitation of RNA
polymerase II and XAB2. Immunoprecipitated fractions from HeLa
WCE with preimmune serum (negative control; lane 1), anti-XAB2
antiserum (lane 2), and anti-RNA polymerase II monoclonal antibody
8WG16 (positive control; lane 3) were analyzed by 8WG16 (upper pan-
el). Immunoprecipitated fractions from HeLa WCE with anti-HA mouse
monoclonal antibody 12CA5 (negative control; lane 1), 8WG16 (lane 2),
and anti-XAB2FL antiserum (positive control; lane 3) were analyzed by
anti-XAB2FL antiserum (lower panel). 5% of the immunoprecipitated
fractions were loaded in positive control lanes.
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with the core NER factor XPA. Our microinjection experiments
revealed that anti-XAB2 antisera caused specific inhibition of
UV-induced UDS in XP-C cells (which only have functional
TCR) and had no significant effect on UV-induced UDS in
normal human cells (predominantly derived from GGR). We
also observed inhibitory effects of anti-XAB2 antisera on recov-
ery of RNA synthesis after UV irradiation in normal human
cells. Together these results indicate that XAB2 is involved in
TCR but not in GGR. In addition, antiserum against the entire
XAB2 (anti-XAB2FL) inhibited transcription in non-UV-irradi-
ated normal cells, strongly suggesting that XAB2 could be a
novel factor involved in the transcription process itself. Since
transcription is essential for TCR, it is likely that the observed
inhibition of TCR is a consequence of the inhibitory effect of
anti-XAB2FL on transcription. However, the anti-XAB2C (the
antiserum against the carboxyl-terminal portion of XAB2) in-
hibited the recovery of RNA synthesis after UV irradiation
without apparent inhibitory effects on transcription. These ob-
servations suggest that besides being involved in transcription,
XAB2 could work as a TCR-specific factor, possibly through the
carboxyl-terminal portion.
The molecular mechanism for the coupling of transcription
and NER in eukaryotes is unknown. Presumably, a lesion on
the transcribed strand is first encountered and marked by an
RNA polymerase II elongation complex (thus bypassing the
need for the XPC-HR23B complex). Then core NER factors are
recruited by TCR-specific proteins such as CSA and CSB (2).
CSB was found in vitro and in vivo to reside in an RNA
polymerase II complex, probably in an elongation mode (21,
25). A quaternary complex consisting of CSB, RNA polymerase
II, template DNA, and nascent RNA has been shown to be able
to recruit TFIIH in vitro (26). The function of CSA is more
obscure. In vitro associations of CSA with various NER factors
have been reported (19), but no stable in vivo association to
either the transcription machinery or to NER factors have been
identified (21). In the present study, we found a dual interac-
tion of part of XAB2 with a fraction of both CSA and CSB as
well as the interaction with XPA. This raises the possibility
that XAB2 links these TCR-specific proteins to assure recruit-
ment and/or access of core NER factors to the lesion identified
by the stalled RNA polymerase II in the elongation complex.
The notion that these interactions are transient may explain
our observation that only a small proportion of XAB2 is bound
to CSA and RNA polymerase II (Figs. 4B and 5C). This is
consistent with the fact that CSA and CSB appear to reside in
different protein complexes (21).
Sequence homology searches using NCBI PSI-BLAST iden-
tified the apparent homologs of XAB2 in D. melanogaster, C.
elegans, and S. pombe. XAB2 also showed a homology, albeit to
a lower degree, to SYF1 of S. cerevisiae (Fig. 2). The sequence
conservation extended over the entire length of XAB2, suggest-
ing an important role of the protein that does not tolerate many
evolutionary changes. An intriguing finding is the presence of
XAB2 in the complete Drosophila genome sequence, in view of
the notion that this organism appears to lack CSA and CSB
homologs (45). This is consistent with an early report that
Drosophila embryonal cells lack detectable TCR (46). The ab-
sence of a TCR pathway in Drosophila supports the idea that
XAB2 has additional functions beyond TCR and is consistent
with a role in the transcription process itself as suggested by
the microinjection experiments.
The homology of XAB2 to SYF1 may provide a clue for
understanding the role of XAB2. Dix et al. (47) described that
the SYF1 gene had been identified as a synthetic lethal mutant
with the CDC40/PRP17 gene, which is involved in S phase
progression of the cell cycle and pre-mRNA splicing in S. cer-
evisiae and that ISY1, interactor of SYF1, was required for
optimal pre-mRNA splicing in S. cerevisiae. In addition, Mc-
Donald et al. (48) reported that CWF3, the S. pombe ortholog of
SYF1, is associated with CDC5, which is required for G2/M
progression of the cell cycle and essential for pre-mRNA splic-
ing. We found that the reported partial amino acid sequences of
CWF3 perfectly match to the S. pombe apparent homolog of
FIG. 6. Inhibitions of recovery of RNA synthesis and transcrip-
tion but not global genome repair by anti-XAB2 antiserum in
vivo. Anti-XAB2FL antiserum was injected into the cytoplasm of binu-
clear cells (indicated by an arrow) obtained after fusion of normal
human fibroblasts. Subsequently the effect on DNA repair synthesis
after UV-irradiation (UDS) predominantly derived from global genome
repair (A), recovery of RNA synthesis after UV irradiation (RRS) (B),
and transcription (normal RNA synthesis without UV- irradiation) (C)
was assessed.
TABLE I
Effect of anti-XAB2 antiserum microinjection on
DNA repair and transcription
Antiserum
UDSa
RRSc Transcriptiond
Wild type XPCb
% % % %
Preimmune 100 100 100 100
Anti-XAB2FLe 94–98 30–55 25–35 41–64
Anti-XAB2Ce 96–98 74 40–55 95–106
Anti-CSB 100 20 37 100
Anti-ERCC1 3–10 NDf 21 100
a Unscheduled DNA synthesis (DNA repair synthesis) levels ex-
pressed as a percentage of UDS compared with noninjected neighboring
cells.
b Percentage of the residual UDS in XP-C cells was 25 6 5% of normal
level.
c Percentage of RNA synthesis recovery after UV exposure in injected
cells compared with noninjected neighboring cells.
d Percentage of overall RNA synthesis in nonirradiated injected cells.
e All experiments were repeated at least three times with the follow-
ing exceptions. Anti-XAB2FL and anti-XAB2C injections into XP-C
cells were performed twice and once, respectively. Given percentages,
expressed as the observed (maximum) variation between different ex-
periments, are derived from autoradiographic grain countings of at
least 100 nuclei.
f ND, not done.
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XAB2. Thus, it is possible that XAB2 is also involved in the
processes associated with cell cycle control and pre-mRNA
splicing in mammalian cells. The SYF1 and CWF3 genes have
been found to be essential for viability in S. cerevisiae (52) and
S. pombe (48), respectively. The requirement of XAB2 in tran-
scription may account for the essential role of SYF1 and CWF3
for viability in yeast. The above findings in yeast fit nicely with
our observation that a significant proportion of XAB2 is in a
complex with the fraction of RNA polymerase II that is associ-
ated with CSB and is thought to be in an elongation mode (21).
Since a tight coupling of transcription elongation and
pre-mRNA splicing has been observed (49, 50), a potential
involvement of XAB2 in pre-mRNA splicing may explain the
inhibition of RNA synthesis observed after microinjection of
anti-XAB2FL as a consequence of impaired splicing giving rise
to arrested transcription. However, it has been reported that
transcription may still occur at normal rates in the absence of
efficient splicing of nascent pre-mRNA during transcription
elongation in human cells (50, 51). Thus, it is likely that the
inhibition of RNA synthesis by anti-XAB2FL resulted from
impaired transcription rather than disturbed pre-mRNA
splicing.
Based on our experimental data and the homology with
CWF3 and SYF1, it is likely that XAB2 is a multifunctional
protein involved in cellular processes such as cell cycle control
and pre-mRNA splicing as well as TCR and transcription in
mammalian cells. Das et al. reported that tandemly arranged
TPR motifs are organized into a regular right-handed super-
helix with a helical repeat of approximately seven TPR motifs
(39). It is proposed that proteins with these structures could
simultaneously interact with multiple target proteins, utilizing
specific combinations of TPR motifs within the superhelix (39).
Since XAB2 harbors 15 tandem arrays of TPR, a possible scaf-
folding function for XAB2 within cellular processes including
NER and transcription is in line with its deduced amino acid
sequence. XAB2 may function as a bridging protein, by simul-
taneously interacting with several other proteins or protein
complexes. In addition, it would be of interest to find out
whether defects in XAB2 also give rise to a human condition,
since both CSA and CSB are associated with the severe neuro-
developmental, UV-sensitive TCR disorder Cockayne
syndrome.
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